Ver­tex taps Verve for gene edit­ing pact — buy­ing a chunk of shares — as Sek Kathire­san steers base edit­ing in­to clin­ic

Al­though Verve Ther­a­peu­tics did not come up with a gene edit­ing tech­nol­o­gy it­self, its work ap­ply­ing base edit­ing in car­dio­vas­cu­lar dis­eases — go­ing from launch to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER